Torrent Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-f22ba176e4725ae988072fad.pdf

Key Takeaways


Merger Integration: The JB Story

Sanjay Gupta: "We're talking about back-office issues. We are not talking about front office customer-facing issues."

Base Business Momentum

Sanjay Gupta: "So I really cannot give guidance today. Best case, I would say, slight decline in the coming quarters, and eventually some stability after maybe three or four quarters."

Cost Synergies & Margin Trajectory

Sudhir Menon: "And having said that, we believe most of it could come through by the next year."

Product & Market-Specific Bets


India Market & Competitive Dynamics

Aman Mehta: " It's very difficult to pinpoint still. ... what is causing the higher, say, 2%, 3% market delta is still difficult to pinpoint exactly."

Guidance & Commitments

CommitmentSpecificsTimeline
JB total business growth recoveryDouble-digit growth in H2 FY27H2 FY27
JB India branded growth accelerationH2 growth higher than H1's 10%H2 FY27
Cost synergy realizationMost of ~₹450 crores achievedBy FY28 (next year)
Combined EBITDA marginGradual increase; H2 FY27 higher than 33.5%H2 FY27
JB EBITDA marginGradual quarter-on-quarter improvementNext 2–3 quarters
R&D spend rangeNot to exceed 4–4.5% of revenueCurrent year and following year
U.S. filings4–5 more products, totaling 9–10 for FY27By fiscal year-end
India MR headcountMaintain at 9,100; potential expansion to 9,500–9,600Through FY27 end; review in a couple of months
Brazil GLP-1 launchOptimistically expect to launchNext 6–9 months
Germany stabilizationEventual stability after slight decline in coming quartersAfter 3–4 quarters
FY28/29 guidanceWill provide guidanceQ1 next year (FY28)

Key Metrics

MetricQ2 FY27
Consolidated revenue₹4,979 cr, up 51% YoY
Operating EBITDA₹1,666 cr, up 54% YoY
Operating EBITDA margin33.5%, vs 33.8% in Q1 FY27; R&D spend increased 0.7 ppt QoQ to 4.2% of revenue
R&D spend4.2% of revenue, up from 3.5% in Q1 FY27; expected range 4% to 4.5% going forward
Net debt to EBITDA1.8x
Torrent base business revenue growth18% YoY
Torrent India base business revenue₹2,181 cr, growth of 20% YoY vs IPM growth of 12%
JB business underlying revenue₹1,086 cr, largely flat YoY
JB India branded business growth7% YoY; H1 FY27 growth at 10%
JB International business growthdown 7% YoY
Curatio business growth34% YoY in Q2 and H1 FY27; now 7% to 8% of base India business vs 4% to 5% at acquisition
Combined India field force strength9,100 (Torrent plus JB) at end of Q2; potential expansion to 9,500–9,600 next year
Semaglutide India franchise market share32% for oral and injectable combined (per PharmaTrac); over 90% share within generic players for oral segment
Brazil constant currency revenueBRL23.6 cr, up 21% YoY; IQVIA growth at 26% vs market growth of 5.7%
U.S. constant currency revenue$44 million, up 13% YoY
Germany constant currency revenueEUR2.6 cr, down 13% YoY
Brazil pipeline53 molecules under ANVISA review, approvals expected in next two years
U.S. filings year-to-date4 products filed, 4 to 5 more expected before fiscal year-end, totaling 9–10 products
Generic semaglutide India estimated first-year market size~₹800 cr, on track to reach that level
Ophthalmology deal second tranche payment~₹950–960 cr, due December of this year
Cost synergy estimate~₹450 cr, with roughly half already reflected in margins; expected to be fully realized in two years instead of three
H2 FY27 JB overall growth guidancedouble-digit; India higher than double-digit, International recovery gradual
H2 FY27 consolidated EBITDA margin outlookhigher than 33.5%, gradual improvement expected
Brazil growth outlookat least superior to 10%, closer to 15% in coming years
ROW markets growth (ex-Brazil branded)6% to 9% conservatively (not JB, total)
IPM growth outlook12% in H1 FY27; expected to sustain for rest of year, next year may drop 1–2% but minimum 10% likely